Serum Vitamin D levels are associated with increased COVID-19

2 severity and mortality independent of visceral adiposity

- 3 Pablo Esteban Vanegas-Cedillo^{1,2}, Omar Yaxmehen Bello-Chavolla^{1,3}, Natalia Ramírez-
- 4 Pedraza⁴, Bethsabel Rodríguez Encinas^{2,} Carolina Isabel Pérez Carrión², María Isabel
- 5 Jasso Ávila², Jorge Carlos Valladares García², Diana Hernández-Juárez², Arsenio Vargas-
- 6 Vázquez, MD^{1,4}, Neftali Eduardo Antonio-Villa^{1,4}, Monica Chapa-Ibarguengoitia⁵, Alfredo
- 7 Ponce de Leon⁶, José Sifuentes-Osornio^{7,8} Carlos A. Aguilar-Salinas^{1,8,9}, Roopa Mehta^{1,2*}
- ⁹ Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
- 10 Médicas y Nutrición Salvador Zubirán (INCMNSZ). ²Department of Endocrinology and
- 11 Metabolism, INCMNSZ, ³Research Division, Instituto Nacional de Geriatría. ⁴MD/PhD
- 12 (PECEM) program, Faculty of Medicine, National Autonomous University of Mexico.
- ⁵Department of Radiology, INCMNSZ, ⁶Department of Infectious Diseases, INCMNSZ,
- ⁷Internal Medicine Division, INCMNSZ ⁸Instituto Tecnologico y de Estudios Superiores de
- 15 Monterrey Tec Salud, ⁹Division of Nutrition, INCMNSZ.
- 16 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- 17 *Correspondence: Roopa Mehta

1

- 18 Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
- 19 Médicas y Nutrición Salvador Zubirán/ Department of Endocrinology and Metabolism,
- 20 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
- 21 Tel +52 (55), 54 87 09 00, 2405. Email: roopamehta@vahoo.com
- 22 3,105 text words; 38 references; 4 tables; 3 figures.
- 23 **Abstract:** 230 words
- 24 Running headline: Vitamin D, adverse COVID-19 outcomes and adiposity

ABSTRACT (229 WORDS) INTRODUCTION: Coronavirus disease (COVID-19) is a global pandemic. Vitamin D (25-OHD) deficiency has been associated with susceptibility to infectious disease. In this study, the association between COVID-19 outcomes and 25-OHD levels in patients attending a COVID-19 reference center in Mexico City are examined. METHODS: Consecutive patients with confirmed COVID-19 were evaluated. All patients underwent clinical evaluation (including outcomes), laboratory measurements (including 25-OHD) and a thoracic computerized tomography (including the measurement of epicardial fat thickness). Low vitamin D was defined as levels <20ng/mL (<50nmol/L) and severely low (or deficient) 25-OHD as a level ≤12ng/mL (<30nmol/L) RESULTS: Of the 551 patients included, low 25-OHD levels were present in 45.6% and severely low levels in 10.9%. Severely low 25-OHD levels were associated with mortality (HR 2.11, 95%CI 1.24-3.58, p=0.006) but not with critical COVID-19 (OR 0.97, 95%CI 0.94-0.99, p=0.042), adjusted for age, sex, body-mass index and epicardial fat. Using model-based causal mediation analyses the increased risk of COVID-19 mortality conferred by 25-OHD levels was partly mediated by its effect on D-dimer and cardiac ultrasensitive troponins. Notably, increased risk of COVID-19 mortality conferred by low vitamin D levels was independent of BMI and epicardial fat. **CONCLUSION:** Vitamin D deficiency (≤12ng/mL or <30nmol/L), is independently

43 44 associated with COVID-19 mortality after adjustment for visceral fat (epicardial fat thickness). Low 25-OHD may contribute to a pro-inflammatory and pro-thrombotic state, 45 46

increasing the risk for adverse COVID-19 outcomes.

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

47 **Keywords:** Vitamin D, COVID-19, SARS-CoV-2, Adiposity, Severe disease

INTRODUCTION

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Coronavirus Disease (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. SARS-CoV-2 spreads primarily by close contact with respiratory droplets from infected individuals and contaminated surfaces (1-3). SARS-CoV-2 infects cells using the angiotensin converting enzyme-2 (ACE-2) receptor; infection can produce an interstitial pneumonia that may progress to acute respiratory distress syndrome (ARDS) and death (4-6). Vitamin D (25-OHD) is a steroid hormone involved in essential physiological roles including preserving bone integrity, immunomodulation by stimulating innate immunity and tempering adaptive immunity, infectious disease prevention and cardiovascular health (7-9). It also acts on the renin angiotensin aldosterone (RAAS) system, inhibiting the angiotensin converting enzyme (ACE, 6). Several factors are known to influence vitamin D levels; lower levels are associated with ethnicity, variation in sun exposure due to higher latitudes, season, time of day, clothing, sunscreen use and skin pigmentation, age, lower sun exposure, obesity and chronic illnesses (10). The presence of obesity results in decreased bioavailability of vitamin D, which is probably related to sequestration into adipose tissue. Furthermore, higher visceral fat content has been shown to be related to a higher incidence of vitamin D deficiency (11). Low levels of 25-OHD have been associated with increased susceptibility to infectious disease, particularly respiratory tract infections (12-14). Several studies have explored the relationship between COVID-19 and vitamin D levels (15-18); however, concerns regarding residual confounding and the lack of mechanistic interpretations for the association of low 25-OHD levels with adverse COVID-19 outcomes requires further studies. Obesity and ethnicity are important risk factors for severe disease, and are also known to modulate vitamin D levels. This may be particularly relevant in Mexico, where

high rates of diabetes and obesity have been associated with an increased risk of severe COVID-19 (19). In this study, the association between COVID-19 outcomes and 25-OHD levels in patients attending a COVID-19 reference center in Mexico City is evaluated. We aim to identify determinants of 25-OHD levels in COVID-19 patients and develop causal-mediation models to propose mechanisms by which Vitamin D may lead to increased

COVID-19 mortality.

METHODS

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Study population

This study included consecutive patients evaluated at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, a COVID-19 reference center in Mexico City between 17th March and 31st May 2020. Subjects were initially assessed at triage and required either ambulatory or in-hospital care for COVID-19 (confirmed with computerized tomography (CT) and/or via RT-qPCR test from nasopharyngeal swabs. All patients had moderate to severe disease as defined by National Institute of Health criteria (Moderate Illness: Evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen (SpO₂) ≥94% on air. Severe Illness: SpO₂ <94% on air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%). Subjects underwent a chest CT, and a radiologist determined the degree of pulmonary parenchymal disease and assessed epicardial fat thickness as a proxy for visceral fat. In addition, a medical history, anthropometric measurements and laboratory tests were obtained, including 25 hydroxy-vitamin D (25(OH)-D). The electronic files of each patient were reviewed to document the outcomes during hospitalization. All proceedings were approved by the research and ethics committee of the INCMNZ (Ref 3383) and informed consent was waived due to the nature of the study.

Laboratory and clinical measurements

Clinical variables and laboratory measures were obtained at the time of initial evaluation. Physical examination included: weight, height, body mass index (BMI, calculated as weight in kilograms divided by squared height in meters), pulse oximeter saturation (SpO2), respiratory rate (RR), temperature and arterial blood pressure (BP). Laboratory measurements included: full blood count and chemistry panel including liver function tests, C-reactive protein (CRP), fibrinogen, D-dimer, ferritin, troponin I (TPNI), erythrocyte sedimentation rate (ESR) and procalcitonin levels. The blood samples were processed in the central laboratory of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vitamin D (25-hydroxivitamin D) was measured by chemiluminescence using the Abbott Architect I2000 equipment. Low levels of vitamin D were defined as <20ng/mL (<50 nmol/L) and severely low (or deficiency) as a level <12ng/mL (<30nmol/L) (6-9).

Epicardial fat measurements

All patients underwent unenhanced CT scans including low-dose CT and two ultra-low-dose CT protocols with commonly reported imaging features of COVID-19 pneumonia. The thoracic CT was performed using a 64-slice scanner (GE MEDICAL SYSTEMS Revolution EVO). Epicardial adipose tissue (EAT) thickness was measured at 3 points (right atrioventricular fossa, left atrioventricular fossa, and anterior interventricular fossa) in the reformatted 4-chamber view using the multiplanar reconstruction (MPR) tool on the workstation (20, 21, 22). The maximum thickness of the EAT was determined from the surface of the myocardium to the pericardium (measured perpendicular to the pericardium). The measurements were made on 2 different occasions, obtaining a total of 6 measurements; the average of them was used for all statistical analyses. Pericardial adipose tissue (PAT) was quantified with the volume measurement tool with the Carestream system of the workstation. The thickness of the thoracic subcutaneous

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

adipose tissue (TscAT) was measured from the anterior border of the sternum to the skin, at the level of the mitral valve in the axial plane of the tomography. The 80th genderspecific percentile of EAT thickness was obtained and used as the threshold to define increased EAT thickness. In addition, chest CT findings were recorded and used to evaluate severity of COVID infection. COVID-19 outcomes Outcomes included mortality and critical disease (defined as the combination of mortality and need for mechanical ventilation /intubation). For time-to-event analyses, time from self-reported symptom onset prior to evaluation until last follow-up (censoring) or death, whichever occurred first was estimated. Statistical analyses Cases with low and severely low vitamin D levels were analyzed using Student's t-test or Mann-Whitney U according to the variable distribution (parametric or non-parametric) for continuous variables. The chi-squared test was applied for categorical variables. Logarithmic, squared root and cubic root transformations were carried out to ensure variable symmetry prior to modeling. All statistical analyses were conducted using R 4.0.2. Prediction of mortality and severe COVID-19 Cox proportional risk regression analyses was used to investigate the association of vitamin D with mortality related to COVID-19. Univariate models and fully adjusted models were generated which included the following covariates: age, gender, BMI, C-reactive protein. D-dimer, ultrasensitive cardiac troponin, epicardial fat, T2D, CKD and oxygen saturation levels. An interaction effect was explored with BMI or BMI categories to rule out the differential impact of vitamin D adjusted for BMI. Model diagnostics were done using Schoenfeld residuals. Finally, the association of vitamin D with requirement for mechanical

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

ventilation or the composite of critical COVID-19 was explored using logistic regression analyses adjusted for the aforementioned covariates. Predictors of vitamin D levels Linear regression analyses were fitted to identify predictors of log-transformed vitamin D levels in patients with COVID-19, and model selection was carried out using minimization of the Bayesian Information Criterion (BIC). Logistic regression models were also fitted using a dummy variable which defined low and severely low vitamin D to identify predictors for these categories and again model selection was conducted using BIC. Finally, model diagnostics for linear regression were conducted using residual analyses and the Hosmer-Lemeshow test for logistic regression analyses. Causal mediation models Finally, to explore whether variables which are influenced by Vitamin D levels may act as a mediator of the risk conferred by Vitamin D on COVID-19 severity, model-based causal mediation analyses were developed: D-dimer and ultrasensitive cardiac troponins were proposed as mediators of the effect of Vitamin D on COVID-19 mortality. All mediation analyses were performed using the mediation R package; to permit inference to obtain a 95% confidence interval using bias-corrected accelerated non-parametric bootstrap. To demonstrate the sequential ignorability assumption, a sensitivity analysis was run to demonstrate residual confounding by varying the correlation between the residuals of both the outcome and the moderator models. Statistical analyses were performed using R software version 4.0.3. A p value <0.05 was considered statistically significant RESULTS Study population This study included 551 patients with confirmed COVID-19 (with compatible computerized tomography findings and/or positive RT-qPCR test from nasopharyngeal swabs) and

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

vitamin D measurements. The mean age of participants was 51.92±13.74 years, with a male predominance (n=355, 64.4%), and a mean BMI of 30.05±5.72. Median follow-up was 15.0 days (IQR 10.0-20.0) and 445 patients required hospitalization (81.1%). Overall, 93 patients received invasive mechanical ventilation (16.88%) and 116 in-hospital deaths (21.1%) were recorded. Type 2 diabetes (T2D) was present in 146 patients (26.9%), 219 patients had obesity (42.7%) and 217 were overweight (42.4%). Mean vitamin D levels were 21.78±9.01 and vitamin D levels below 20ng/mL were present in 251 subjects (45.6%) (Table 1). Extremely low vitamin D levels (≤12ng/mL) were observed in 59 patients (10.7%) (Table 1 supplementary material). Determinants of Vitamin D levels amongst patients with COVID-19 The pathophysiological adaptations to COVID-19 may be predictive of low vitamin D levels. To this end, determinants of low vitamin D in COVID-19 were sought in an attempt to develop a mechanistic explanatory model for this relationship. Subjects with low vitamin D levels (<20mmq/dl) were more likely to be female, have type 2 diabetes, higher HbA1c, D-dimer and ferritin levels and lower oxygen saturation, albumin and C-reactive protein. Using linear regression, a lower log-transformed vitamin D level was independently associated with female gender, higher log-transformed ultrasensitive cardiac troponin, higher log-transformed D-dimer, higher log-transformed epicardial fat area, and lower Creactive protein levels (**Table 2**). When exploring a model to detect low vitamin D levels. there was a significantly higher odds for log-transformed D-dimer levels (OR 1.31, 95%CI 1.06-1.63); lower odds were associated with male gender (OR 0.45, 95%CI 0.31-0.65), higher oxygen saturation levels (OR 0.98, 95%Cl 0.97-0.99) and higher C-reactive protein values (OR 0.75, 95%CI 0.61-0.92), adjusted for age, and log-transformed epicardial fat. There was no association between days from symptom onset and vitamin D levels at admission.

Vitamin D levels and COVID-19 mortality Overall, vitamin D levels were significantly lower when comparing non-fatal to fatal COVID-19 cases (22.41±9.34 vs. 19.44±67.19, p<0.001). When assessing risk related to the association between mortality and vitamin D levels using Cox regression, a 1-unit increase in vitamin D levels was associated with a decreased risk of COVID-19 mortality. Interestingly, when stratifying cases according to gender, the difference in vitamin D levels between fatal and non-fatal cases was greater in women compared to men and lower in cases with obesity (Figure 1). When the mortality models were adjusted for age, gender, BMI, and C-reactive protein, CKD and T2D the observed association between vitamin D levels and a decrease in COVID-19 mortality persisted (Table 3). There was no significant interaction with BMI, (as a continuous variable or categorized) in normal weight, overweight and obese with vitamin D levels. Using post-estimation simulation to predict risk associated with changes in vitamin D levels using the simPH R package, there was a steady decrease in risk attributable to increasing vitamin D concentrations using vitamin D <20ng/mL and ≤12ng/mL as thresholds (Figure 2). Vitamin D and critical COVID-19 When assessing the impact of vitamin D on the risk of invasive mechanical ventilation there was no significant association even after adjustment for age, gender, BMI, C-reactive protein, CKD or T2D status (OR 0.986, 95%CI 0.957-1.015, p=0.366). However, when assessing the composite of critical COVID-19 using logistic regression models, lower vitamin D levels were associated with critical COVID-19 (OR 0.97, 95%CI 0.94-0.99, p=0.042, adjusting by age, gender, BMI, C-reactive protein, D-dimer, CKD, SpO2 or T2D

Causal mediation models

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

status).

Finally, model-based causal mediation models were developed to assess whether the effect of vitamin D (E) on increased mortality risk (Y) was mediated through changes in variables identified in **Table 2** (M), adjusted for age, gender, BMI and epicardial fat. The direct effect of vitamin D on increased mortality risk was significant ($\Delta_{E\rightarrow Y}$ -0.144, 95%CI -0.069, -0.010) and the indirect effect of vitamin D, mediated by increase D-dimer levels ($\Delta_{E\rightarrow MY}$ -0.035, 95%CI -0.164, -0.010), represented 19.3% (95%CI 9.5-77.0%) of the overall association of vitamin D on mortality. A similar scenario was observed for cardiac troponins, whereby both the direct effect of vitamin D on mortality ($\Delta_{E\rightarrow Y}$ -0.133, 95%CI -0.150, -0.020) and the indirect effect mediated by ultrasensitive cardiac troponins ($\Delta_{E\rightarrow MY}$ -0.047, 95%CI -0.085, -0.020), were significant and represented 26.2% (95%CI 14.9-73.0%) of the overall effect of vitamin D on mortality. Notably, there were no significant causal mediation models for either BMI or epicardial fat, here there was only a direct effect on mortality, independent of vitamin D levels.

DISCUSSION

In this study, the association between vitamin D levels and severity of COVID-19 was explored in a Mexican population. Severely low levels of vitamin D (deficiency) showed a clear association with mortality, even after adjusting for confounders, including epicardial fat as a proxy of visceral fat and BMI. A vitamin D level <20ng/mL (<50nmol/L), showed a strong negative predictive value, suggesting that when levels are adequate, the probability of mortality is low. Furthermore, the increased risk of mortality from COVID-19 was partly mediated by the effect of vitamin D on markers of disease severity, such as D-dimer and ultrasensitive cardiac troponins, independent of BMI and epicardial fat (these showed effects on COVID-19 mortality independent of vitamin D levels). This suggests that vitamin D may be a marker of an impaired response to infection within the pulmonary epithelium, in particular in those with severe deficiency (23).

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

Several studies have explored the relationship between COVID-19 and vitamin D levels (15-17, 24). These include those examining vitamin D levels and risk of infection and those examining an association with severity of COVID-19. Higher levels of IL-6 were observed in the vitamin D deficient group suggesting a greater inflammatory response in these patients (18). A recent systematic review and meta-analysis reported that vitamin D deficiency was not associated with increased risk of infection, but severe cases presented with greater vitamin D deficiency compared with mild cases. Vitamin D deficiency has been associated to increased hospitalization and mortality risk from COVID-19 (19). Physiological mechanisms by which vitamin D exerts a protective function include enhanced innate immunity including augmentation of physical barriers to infection and optimization of adaptive immunity (25). Adequate vitamin D levels favor protective tissue maintenance, preserving tight, gap and adherens junctions, all of which are disturbed by viruses (26). Calcitriol (1,25 OH D) induces production of cathelicidins, LL-37 and betadefensins, proteins associated with viral surface disruption and reduced viral replication rates, lower pro-inflammatory cytokine (e.g. tumor necrosis factor alpha, interleukin-6) accumulation in target tissues such as the lungs and increased anti-inflammatory cytokine concentrations that defend against viral infections (27). In addition, vitamin D enhances macrophage phagocytosis and efferocytosis (allowing removal of cellular debris preventing further inflammation), and regulation of the macrophage oxidative burst (eliciting a more potent and efficient oxidative surge) (24). Vitamin D also has a modulatory effect on the inflammatory response caused by COVID-19. It curbs adaptive immunity by inhibiting B cell proliferation, differentiation and production of antibodies and plays a role in regulation the T cell phenotype (28). Vitamin D suppresses helper T cells (Th)1 proliferation, thus decreasing the synthesis of cytokines such as interferon-gamma, interleukin-2 and interleukin-10 (6) (27, 29) This reduction in

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

cytokines, suppresses antigen presentation on dendritic cells and diminishes T lymphocyte recruitment and proliferation. Thus, there is a shift in the adaptive immune response from Th1 to a more regulatory Th2 response, characterized by an increase in expression of Th2 associated cytokines (IL-4, IL-10) (30, 31). This may attenuate the quantity of proinflammatory cytokines that are associated with severe infection (32) In addition, vitamin D induces ACE 2 expression, and suppresses the angiotensin-renin system, thus reducing levels of proinflammatory angiotensin II. Hence, vitamin D deficiency, could potentiate the cytokine storm perpetuating a pro-inflammatory state and worsening pulmonary outcomes (33). Finally, thrombotic complications are common in such patients; vitamin D is also involved in the regulation of thrombotic pathways (29). In our study, low vitamin D levels in COVID-19 patients were related to inflammatory, pro-thrombotic and metabolic markers of severity, confirming observations from previous studies. Adverse COVID-19 outcomes have been linked to the ethnic origin of the population under study; this has also been associated with the presence of vitamin D deficiency. Asians, African Americans, and ethnic minorities are at an increased risk of mortality from COVID-19 (34). This may partly be due to a decrease in the production of vitamin D dependent on UV rays. This is related to the skin levels of melanin present in these populations and on the unequal distribution of poverty and cardiometabolic disease rates across such ethnicities. This finding is relevant and may explain lower vitamin D levels and severity of COVID-19 in México in a previous study (35). Previous reports in similar populations, including Hispanics, have shown higher risk of SARS-CoV-2 infection, compared to Caucasian population (36). Currently, routine vitamin D supplementation in hospitalized patients with COVID-19 is not recommended (37). A recent pilot study showed that administration of a high dose of calcifediol or 25-hydroxyvitamin D, significantly reduced the need for intensive care in

hospitalized patients (38). The authors speculate that calcifediol may reduce severity of the disease. Ideally, additional large randomized controlled trials are needed to properly assess this claim and whether vitamin D supplementation can significantly impact population risk. This study has certain strengths and limitations. It included a large number of patients with heterogenous risk profiles in whom a variety of disease severity parameters were measured. In addition, a series of statistical tests were carried out to ensure minimal possibility of residual confounding. Nevertheless, some limitations must be acknowledged in order to properly interpret this study. First, a chemiluminescence immunoassay was used to assess vitamin D levels, this may lead to inconsistent results compared to other techniques including competitive binding protein - CBP, radioimmunoassay - RIA liquid chromatography - LC, UV detection with liquid chromatography and liquid chromatography mass spectrometry LCMS or tandem mass spectrometry. Since most patients were attended in the institution for the first time for COVID-19, historic vitamin D values were not available to assess the effect of vitamin D dynamics on infection risk or outcomes. Furthermore, given the disease course of COVID-19, severity profiles are highly heterogeneous even amongst hospitalized patients, which may influence vitamin D values on the basis of varying severity; control for this factor using propensity score matching was carried out, however, there remains a possibility for residual confounding. Notably, these results are from a COVID-19 reference center in Mexico City, this could reduce the representativeness of the findings. Further evidence in other regions of Mexico to confirm the role of vitamin D as a marker of disease severity and mortality in Mexicans with COVID-19 is needed.

Conclusions

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Vitamin D levels lower or equal to 12 ng/ml (30nmol/L) are independently associated with COVID-19 mortality, even after adjusting for confounders (including measures of visceral and total body fat). No association was confirmed between vitamin D levels and the need for intubation. Vitamin D deficiency is more prevalent in women and patients with type 2 diabetes mellitus. Vitamin D supplementation may be considered in deficient patients, but evidence of benefit is required from double blind randomized controlled trials.

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

CONFLICT OF INTEREST/FINANCIAL DISCLOSURE: Nothing to disclose. DATA AVAILABILITY: Data is available from the corresponding author upon reasonable request. Code for reproducibility of results available at: https://github.com/oyaxbell/covid metabolism FUNDING: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. **ACKNOWLEDGMENTS** All authors approved the submitted version. All the authors would like to thank the staff of the Endocrinology and Metabolism Department for all their support. We are thankful to the study volunteers for all their work and support throughout the realization of the study. AVV, and NEAV are enrolled in the PECEM program at the Faculty of Medicine of UNAM; AVV and NEAV are supported by CONACyT. CONTRIBUTIONS: research idea and study design: RM, OYBC, CAAS; data acquisition: RM, PEVC, NRP, MAJA, CIPC, BRE, JCVG, CAAS; data analysis/interpretation: OYBC, RM, CAAS, NEAV, AVV; statistical analysis: OYBC, NEAV; manuscript drafting: RM, OYBC, NEAV, AVV, CAAS; supervision or mentorship: RM, CAAS, APL, JSO. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

REFERENCES

- 1. CDC, How COVID-19 Spreads. https://www.cdc.gov/coronavirus/2019-ncov/preve
- 351 nt-getting-sick/how-covid -spreads.html. 2020
- 2. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on
- 353 coronavirus disease 2019 (COVID-19) outbreak an update on the status. Mil Med
- 354 Res. 2020;7(1):11
- 355 3. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with
- 356 2019 novel coronavirus in Wuhan. China Lancet Lond Engl. 2020;395:497-506
- 4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
- epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
- 359 binding. Lancet. 2020; 395(10224):565–574.
- 5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
- SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
- observational study. Lancet Respir Med. 2020;8: 475-481.
- 363 6. Mahdavi A M. A brief review of interplay between vitamin D and angiotensin
- 364 converting enzyme 2: Implications for a potential treatment for COVID-19. Rev Med
- 365 Virol. 2020;1–6.
- 7. Tangpricha V. Pearce EN. Chen TC. Holick MF. Vitamin D insufficiency among
- free-living healthy young adults. Am J Med. 2002;112:659-662
- 368 8. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas
- AG, Boland R, Ferrucci L, and Bikleet DD. Vitamin D: beyond bone. Ann N Y Acad
- 370 Sci. 2013;1287:45–58.
- 9. Zemb P, Bergman P, Camargo CA, Jr, Cavalier E, Cormier C, Courbebaisse M,
- Hollis B, Joulia F, Minisola S, Pilz S, Pludowski P, Schmitt F, Zdrenghea M, and

374

375

378

379

383

385

387

388

389

393

395

Souberbielle JC. Vitamin D deficiency and the COVID-19 pandemic. J Glob Antimicrob Resist. 2020 Sep; 22: 133-134 10. Tsiaras WG and Weinstock MA. Factors influencing vitamin D status. Acta Derm 376 Venereol 2011 Mar;91(2):115-24 11. Kim YA, Cho YJ. The association between visceral fat, subcutaneous fat and 377 serum 25-hydroxyvitamin D3 levels. Obesity Medicine 13 (2019) 29–33 12. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet 380 Diabetes Endocrinol 2020 Jul;8(7):570 381 13. Greiller CL and Martineau AR. Modulation of the Immune Response to Respiratory 382 Viruses by Vitamin D. Nutrients 2015, 7, 4240-4270 14. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-384 Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees 386 JR, Simpson S Jr, Stelmach I, Trilok Kumar G, Urashima M and Camargo CA Jr. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data BMJ 2017;356:i6583 15. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, Keller 390 F,Cantù M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with 391 Positive PCR for SARS CoV-2. Nutrients. 2020 May 9; 12:1359. 392 16. Meltzer DO, Best TJ, PhD, Zhang H, Vokes T, Arora V and Solway J, Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test 394 Results. JAMA Network Open. 2020;3(9):e2019722 17. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ, 396 Munroe PB, Harvey NC, Petersen SE. 2020 Greater risk of severe COVID-19 in

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413 414

415

416

417

418

419

420

Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J Public Health (Oxf) Aug 18;42(3):451-460 18. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, and Merle U (2020) Vitamin D deficiency and outcome of COVID 19 patients. Nutrients 12:2757. https://doi.org/10.3390/nu12092757 19. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázguez A, González-Díaz A, Márquez-Salinas A, Fermín-Martínez CA, Naveja JJ, Aguilar-Salinas CA. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol 1:105(8):dgaa346. Metab. 2020 Aug doi: 10.1210/clinem/dgaa346. 20. Tzung-Dau Wang, et. al. 2009, Relations of Epicardial Adipose Tissue Measured by Multidetector Computed Tomography to Components of the Metabolic Syndrome Are Region-Specific and Independent of Anthropometric Indexes and Intraabdominal Visceral Fat. J Clin Endocrinol Metab, 94(2):662–669. 21. Michael T. Lu, MD. 2007, Reformatted Four-Chamber and Short-Axis Views of the Heart Using Thin Section (≤2 mm) MDCT Images. Acad Radiol 2007; 14:1108-1112 22. Angela Gallina Bertaso, 2013. Epicardial Fat: Definition, Measurements and Systematic Review of Main Outcomes. DOI: 10.5935/abc.20130138 23. Evans RM and Lippman SM. Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell Metabolism. 2020 Nov 3; 32(5):704-709

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

24. McCartney DM, O'Shea PM, Faul JL, Healy MJ, Byrne G, Griffin TP, Walsh JB, Byrne DG and Kenny RA. Vitamin D and SARS-CoV-2 infection—evolution of evidence supporting clinical practice and policy development. A position statement from the Covit-D Consortium. Irish Journal of Medical Science (1971 -) https://doi.org/10.1007/s11845-020-02427-9 25. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N, Landry DW and Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. Eur J Endocrinol. 2020 Nov;183(5):R133-R147 26. Brown, R. 2020. Vitamin D deficiency: a factor in COVID-19, progression, severity and mortality? - An urgent call for research. Mito Fit Preprint Arch., 1-29., (28. Schwalfenberg, G. K. 2011. A review of the critical role of vitamin D deficiency. Mol. Nutr. Food Res. 55, 96-108.28 27. Grant W, L. H. 2020. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, 1-19 28. Wei Shan Hoong C, Huilin K, Cho S, Meyyur Aravamudan V and Hui Xian Lin J. Are Adequate Vitamin D Levels Helpful in Fighting COVID-19? A Look at the Evidence. Horm Metab Res. 2020 Nov; 52(11):775-783 29. E. Laird, J. R. 2020. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Irish Medical Journal, 81. 30. Jeffery, L. 2009, 1,25-dihydroxyvitamin D3 and interleukin-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. Journal of Immunology, 5458–5467. 31. Baeke, F., Takiishi, T. 2010. Vitamin D: modulator of the immune system. Current Opinion in Pharmacology, 482–496.

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

32. Maghbooli Z, S. M. 2020. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One, 1-13. 33. Carpagnano G, D. L. 2020. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. Journal of Endocrinological Investigation, 1-7 34. Weir, E. 2020. Does vitamin D deficiency increase the severity of COVID-19? Clinical Medicine, 1-2. 35. Rodriguez Tort, A. 2020. La deficiencia de vitamina D es un factor de riesgo de mortalidad en pacientes con COVID-19. Rev Sanid Milit Mex, 106-113. 36. Pan et al. 2020. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine, 1-8. 37. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, Macedo MB, MD, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ, Antonangelo L, Caparbo VF, Gualano B, Pereira RMR, MD. Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial. doi: 10.1101/2020.11.16.20232397 38. Márquez-Salinas A. Fermín-Martínez CA, Antonio-Villa NE, Vargas-Vázquez A, C. Guerra E, Campos-Muñoz A, Zavala-Romero L, Mehta R, Bahena-López JP, Ortiz-Brizuela R, González-Lara MF, Roman-Montes CM, Martinez-Guerra BA, Ponce de Leon A, Sifuentes-Osornio J, Gutiérrez-Robledo LM, Aguilar-Salinas CA, Bello-Chavolla OY medRxiv 2020.11.03.20225375; doi: 10.1101/2020.11.03.20225375

470 **Table 1.** Clinical characteristics, imaging findings and severity scores in patients with

COVID-19, comparing cases with and without low vitamin D levels.

TABLES

469

	Vitamin D	Vitamin D	
Parameter	[>20 ng/mL]	[≤20 ng/mL]	P-value
	(n=300)	(n=251)	
Age (years)	53.0 (±14.92)	51.0 (±12.60)	0.088
Male Sex (%)	219 (73%)	136 (54.2%)	<0.001
Low-Socioeconomic Status (%)	203 (67.66%)	172 (68.5%)	0.902
Critical outcome (%)	85 (28.3)	81 (32.3)	0.363
Intubation (%)	53 (17.6)	40 (15.9)	0.670
Mortality (%)	57 (19)	59 (23.5)	0.23
Arterial Hypertension (%)	83 (27.94%)	89 (35.9%)	0.058
Type 2 diabetes (%)	68 (22.9%)	78 (31.6%)	0.031
Time since diagnosis (years)	9.8 (±7.8)	9.20 (±7.5)	0.831
Obesity (%)	118 (39.9%)	111 (44.9%)	0.269
Smoking status (%)	15 (5.8%)	12 (5.8%)	0.789
CKD (%)	6 (2.0%)	12 (4.9%)	0.111

CVD (%)	6 (2.0%)	10 (4.0%)	0.258
Cirrhosis (%)	0 (0%)	3 (1.21%)	0.186
BMI (kg/m2)	29.83 (±4.92)	30.32 (±6.56)	0.343
Respiratory Rate (rpm)	28.52 (±12.40)	28.31 (±9.11)	0.821
Heart Rate (bpm)	102.31 (±18.2)	101.85 (±18.5)	0.771
Systolic Arterial Pressure (mmHg)	120 (110-131)	123 (110-135)	0.264
Diastolic Arterial Pressure (mmHg)	76 (70-80)	74 (67-81)	0.322
Oxygen saturation (%)	82.65 (±11.4)	79.89 (±13.4)	0.010
C-reactive protein	14.93 (9.02- 23.20)	13.6 (6.37-21.76)	0.052*
Glucose levels (mg/dL)	149.7 (±85.73)	163.6 (±97.98)	0.0805*
HbA1c (%)	6.10 (5.8-7.05)	6.85 (6.0-9.6)	0.0040
Triglycerides (mg/dL)	149 (114-192)	140 (110-179)	0.2907
HDL-C (mg/dL)	32.7 (±15.25)	33.3 (±10.71)	0.9111
LDL-C (mg/dL)	95.9 (±57.38)	75.1 (±34.74)	0.2818
Total Cholesterol (mg/dL)	159.5 (±60.93)	135.7 (±44.23)	0.2658

Hemoglobin (%)	15.45 (1.85)	17.42 (22.99)	0.1794
Platelet Count ()	230.97 (90.89)	236.53 (103.83)	0.5089
Lymphocytes	8.91 (4.35)	9.16 (4.93)	0.5287
Neutrophils	6435.0 (4699.1)	6336.8 (5227.20)	0.8187
Serum Creatinine (mg/dL)	0.95 (0.79-1.15)	0.91 (0.74-1.16)	0.6451
Ferritin (mg/dl)	656.0 (323.3- 1138.7)	553.3 (284.7-959.7)	0.06174*
D-Dimer	629 (401-1049)	821 (454-1376)	0.00071
Protrombin	11.4 (10.8-12.4)	11.4 (10.6-12.5)	0.3642
Fibrinogen	697.0 (556.5- 854.5)	672 (482-789)	0.01406
BUN	18.1 (11.6)	20.7 (17.7)	0.0539*
AST	42.6 (30.5-62.5)	41.4 (30.1-64.7)	0.6787
ALT	35.9 (23.7-55-1)	33.50 (23.8-58.2)	0.6321
Albumin	3.8 (3.44-4.01)	3.6 (3.26-3.96)	0.0024
Lactate dehydrogenase	361 (291-466)	374 (278.5-498.5)	0.7565
СК	116 (64-236)	104.5 (55-225.3)	0.1976
Procalcitonin	0.270 (0.06-	0.32 (0.15-1.22)	0.2991

	0.57)		
Symptoms (n)	5 (3-5)	4 (3-5)	0.107
Comorbidities (n)	1 (0-1)	1 (0-2)	0.001
Time hospitalized (days)	6 (3-10)	6 (3-10)	0.995
CT findings			
Epicardial fat (%)	9.3 (7.3-11.7)	10 (8.2-12.2)	0.011
Pericardial fat (%)	185 (61.7)	145 (57.8)	0.407
Subthoracic fat (%)	15 (10-21)	17 (12-24)	0.010
Ground Glass Opacity (%)	297 (99)	248 (98)	0.710
Consolidations (%)	158 (53.6)	136 (54.2)	0.781
GGO + Consolidations (%)	158 (53.6)	136 (54.2)	0.721
Lobules afected 1 2 3	34 (11.3) 82 (32.7) 132 (52.6)	34 (11.3) 125 (41.7) 140 (46.6)	0.178
Hepatic Steatosis (%)	99 (33)	90 (35.9)	0.539
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.733
QSOFA (pts)	1 (1-1)	1 (1-1)	0.329

CURB-65 (pts) 1 (0-2) 1 (0-2) 0.347

Table 2. Multiple linear regression model to identify determinants of Vitamin D levels in patients with COVID-19.

Model	Danamatan	β-	050/01	4	P-
Model	Parameter	coefficient	95%CI	t	value
	Intercept	3.515	3.177-3.853	20.426	<0.001
	Male Sex	0.168	0.097 -0.238	4.668	<0.001
\ <i>"</i>	Ultrasensitive troponin	-0.033	-0.0630.002	-2.124	0.034
Vitamin D R ² =0.1091	D-dimer	-0.060	-0.1000.020	-2.951	0.003
	C-reactive protein	0.065	0.026-0.103	3.265	0.001
	Epicardial fat	-0.126	-0.2220.031	-2.599	0.010
	Type 2 diabetes	-0.072	-0.147 – 0.004	-1.871	0.062

Table 3. Cox proportional risk regression models to predict mortality related to COVID-19 using Vitamin D levels adjusted for covariates. Model 1: Unadjusted, Model 2: Adjusted for age, gender, body-mass index (BMI) and C-reactive protein (CRP), Model 3: Model 2 adjusted for chronic kidney disease (CKD), epicardial fat and type 2 diabetes (T2D.

Model	Parameter	β- coefficient	HR (95%CI)	P-value
Model 1 c-statistic=0.566	Vitamin D	-0.036	0.965 (0.942-0.988)	0.003
	Vitamin D	-0.043	0.938 (0.934-0.983)	0.001
	Age	0.037	1.037 (1.022-1.052)	<0.001
Model 2 c-statistic=0.694	Male gender	0.787	2.196 (1.373-3.512)	0.001
C-Statistic=0.094	ВМІ	0.038	1.039 (1.005-1.073)	0.024
	CRP	0.004	1.004 (1.002-1.007)	<0.001
	Vitamin D	-0.039	0.962 (0.935-0.989)	0.006
	CKD	0.301	0.749 (0.276-2.030)	0.570
Model 3	T2D	0.325	1.384 (0.882-2.170)	0.157
c-statistic=0.702	Ultrasensitive cardiac	0.170	1.185 (1.002-1.403)	0.048
	troponin			
	D-dimer	0.003	1.003 (0.804-1.252)	0.980

Oxygen saturation	-0.026	0.975 (0.960-0.990)	0.001
Epicardial fat thickness	0.669	1.952 (0.501-7.607)	0.335

Table 4: Causal mediation analyses predicting the effect of Vitamin D levels (E) mediated by elevated D-dimer, ultrasensitive cardiac troponins or low SpO2 (M) on severe COVID-19 and mortality (Y), adjusted by gender, age, BMI and epicardial fat. **Abbreviations:** ACME: average causal mediation effects; ADE: average direct effects; SpO2: Oxygen saturation levels.

Efector (E)	Mediator	ACME	ADE	Total Effect	Proportion Mediated
Outcome (Y) Efector (E)	(M)	(95%CI)	(95%CI)	(95%CI)	(95%CI)
	D-dimer	-0.035	-0.144	-0.179	19.3%
D diffici	2 (11110)	(-0.069,-0.010)	(-0.164, -0.10)	(-0.188,-0.050)	(9.5-77.0%)
Vitamin D	Ultrasentivie	-0.047	-0.133	-0.181	26.2%
VIGITIII D	cardiac troponins	(-0.085, -0.020)	(-0.150, -0.020)	(-0.183, -0.060)	(15.0-73.0%)
	\$202	-0.037	-0.144	-0.181	20.3%
	S ρΟ2	(-0.066, -0.010)	(-0.159, -0.030)	(-0.186,-0.050)	(9.7-64.0%)
	Efector (E) Vitamin D	Efector (E) (M) D-dimer Ultrasentivie Vitamin D	Efector (E) (M) (95%CI) D-dimer -0.035 (-0.069,-0.010) (-0.069,-0.010) Vitamin D Ultrasentivie cardiac troponins (-0.085, -0.020) SpO2 -0.037	Efector (E) (M) (95%CI) (95%CI) D-dimer -0.035 -0.144 (-0.069,-0.010) (-0.164, -0.10) Vitamin D Ultrasentivie -0.047 -0.133 Cardiac troponins (-0.085, -0.020) (-0.150, -0.020) SpO2 -0.037 -0.144	Efector (E) (M) (95%CI) (95%CI) (95%CI) D-dimer -0.035 -0.144 -0.179 (-0.069,-0.010) (-0.164, -0.10) (-0.188,-0.050) Vitamin D Ultrasentivie -0.047 -0.133 -0.181 cardiac troponins (-0.085, -0.020) (-0.150, -0.020) (-0.183, -0.060) SpO2 -0.037 -0.144 -0.181

FIGURE LEGENDS

488

489

490




Figure 1. Boxplots comparing Vitamin D levels according to the need for invasive mechanical ventilation (IVM) or lethal COVID-19 stratified by gender (A-B) and by body-mass index categories (C-D).

495




Figure 2. Post-estimation simulation of Vitamin D levels to predict COVID-19 lethality, adjusted for age, sex, BMI, C-reactive protein, epicardial fat, D-dimer, oxygen saturation, T2D, and CKD using Vitamin D cut-offs of <20ng/dL (A) and ≤12ng/mL




Figure 3. Model-based causal mediation analyses to investigate the role of Vitamin D on COVID-19 mortality mediated by D-dimer (A), ultrasensitive cardiac troponins (B)

Supplementary Material

510

511

Table 1. Clinical characteristics, imaging findings and severity scores in patients with COVID-19, comparing cases with and without severely low vitamin D levels (vitamin D deficiency).

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Age (years)	51.6 (13.7)	54.9 (13.9)	0.0865
Male Sex (%)	327 (66.2)	28 (49.2)	0.01626
Severe outcome (%)	142 (28.7)	24 (42.1)	0.0537
Intubation (%)	83 (16.8)	10 (17.4)	0.981
Letality (%)	95 (19.23)	21 (36.8)	0.0035
Low-Socioeconomic Status (%)	336 (68)	39 (68.3)	0.921
Arterial Hypertension (%)	150 (30.7)	22 (38.6)	0.293
Type 2 diabetes (%) Time since diagnosis (years)	124 (25.5) 9.1 (7.14)	22 (38.6) 11.6 (9.78)	0.0512 0.297
Obesity (%)	204 (41.9)	25 (44.6)	0.8008
Smoking status (%)	26 (6.25)	1 (1.75)	0.921
CKD (%)	15 (3.10)	3 (5.26)	0.637
CVD (%)	14 (2.88)	2 (3.51)	0.921
Cirrhosis (%)	2 (0.41)	1 (1.75)	0.7256
BMI (kg/m2)	30.0 (5.29)	30.5 (8.76)	0.7227
Respiratory Rate (rpm)	28.4 (11.4)	28.7 (6.9)	0.7946

Heart Rate (bpm)	102.5 (18.3)	98.8 (18.3)	0.1545
Systolic Arterial Pressure (mmHg)	122 (110-132)	120 (110-136)	0.3157
Diastolic Arterial Pressure (mmHg)	75 (70-80)	73 (66-80)	0.242
Oxygen saturation (%)	81.7 (12.2)	78.8 (13.8)	0.1302
C-reactive protein	14.7 (7.8-21.9)	12.8 (6.7-27.9)	0.8042

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Glucose levels (mg/dL)	152 (85.8)	185 (129.7)	0.0689
HbA1c (%)	6.3 (5.9-7.6)	8.0 (6.3-10.6)	0.00312
Triglycerides (mg/dL)	141 (111-183)	164 (118-237)	0.07487
HDL-C (mg/dL)	33 (13.4)	33 (7.78)	0.981
LDL-C (mg/dL)	84.7 (45.8)	80.3 (55.0)	0.887
Total Cholesterol (mg/dL)	147.7 (50.9)	135 (67.7)	0.7396
Hemoglobin	16.1 (12.3)	18.4 (28.9)	0.5584
Platelet Count	232.1 (95.5)	245.8 (108.9)	0.364
Leucocytes	8.96 (4.5)	9.62 (5.7)	0.4071

Neutrophils	6300.9 (4777.395)	7157.1 (6186.3)	0.3161
Serum Creatinine (mg/dL)	0.93 (0.77-1.15)	0.90 (0.75-1.19)	0.6636
Ferritin (mg/dl)	613 (287-1.069)	610 (389-984)	0.9173
D-Dimer	670 (413-1,178)	949 (567-1,803)	0.0025
Protrombin	11.4 (10.8-12.5)	11.4 (10.6-12.5)	0.4982
Fibrinogen	680 (526-820)	705 (464-896)	0.8438
BUN	18.8 (13.9)	23.9 (20.5)	0.0711
AST	41.9 (30.3-62.72)	42.6 (30.3-65.1)	0.6716
ALT	34.9 (23.9-56.8)	33.5 (22.3-53.6)	0.5808
Albumin	3.72 (3.38-4.00)	3.34 (2.93-3.77)	0.001
DHL	358 (283-476)	402 (316-521)	0.06721
CK	110 (61-229)	103 (55-250)	0.6239
Procalcitonina	0.27 (0.07-0.56)	3.045 (3.03-3.88)	0.034

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Symptoms (n)	4 (3-5)	4 (3-5)	0.162

Comorbid conditions (n)	1 (1-2)	2 (1-3)	0.042
Time hospitalized (days)	6 (3-10)	6 (3-8)	0.489
CT findings			
Epicardial fat (%)	9.7 (7.7-11.8)	10.2 (8.0-12.7)	0.105
Pericardial fat (%)	296 (59.4)	34 (59.6)	0.942
Subthoracic fat (%)	16 (11-22)	17 (12-25)	0.225
Ground Glass Opacity (%)	488 (98.8)	57 (100)	0.747
Consolidation (%)	258 (52.2)	36 (63.1)	0.162
GGO + Consolidation (%)	257 (52%)	36 (63.1)	0.154
Lobules afected 1 2 3	65 (13.1) 190 (38.5) 239 (48.4)	7 (12.3) 17 (29.8) 33 (57.8)	0.553
Hepatic Steatosis (%)	172 (34.8)	17 (29.8)	0.545
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.694
QSOFA (pts)	1 (1-2)	1 (1-2)	0.785
CURB-65 (pts)	1 (0-2)	1 (0-2)	0.341